Drug-induced ventricular tachyarrhythmias can be caused by cardiovascular drugs,
noncardiovascular drugs, and even nonprescription agents. They can result in arrhythmic …

Defining an appropriate and efficient assessment of drug‐induced corrected QT interval
(QTc) prolongation (a surrogate marker of torsades de pointes arrhythmia) remains a …

The mouse is the animal model principally used to study biological processes in mammals.
The mutation, overexpression or knockout of one or several genes can provide insight into …

Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) and higher
throughput platforms have emerged as potential tools to advance cardiac drug safety …

Dilated cardiomyopathy (DCM) is one of the leading causes of heart failure and heart
transplantation. A portion of familial DCM is due to mutations in the LMNA gene encoding …

Long‐QT syndrome (LQTS) is an arrhythmogenic disorder characterised by prolongation of
the QT interval in the electrocardiogram, which can lead to sudden cardiac death …

Background and purpose: Assessing the proarrhythmic potential of compounds during drug
development is essential. However, reliable prediction of drug‐induced torsades de pointes …

Torsade de pointes (TdP) is a stereotyped polymorphic ventricular tachycardia characterized
by a cyclic shifting of the QRS axis (twisting around the points of the isoelectric line) …

ATP‐dependent potassium channel openers such as pinacidil and levcromakalim have long
been known to shorten action potential duration and to be profibrillatory in non‐clinical …

Aims Torsades de pointes arrhythmias (TdP) occur by definition in the setting of prolonged
QT intervals. Animal models of drug induced Long-QT syndrome (dLQTS) have shown …